$TOVX
Theriva Biologics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000141057824001342 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.302M $1.467M
YoY Change 985.85% -45.46%
% of Gross Profit
Research & Development $2.734M $2.953M
YoY Change -31.75% -5.75%
% of Gross Profit
Depreciation & Amortization $33.00K $38.00K
YoY Change -8.33% 26.67%
% of Gross Profit
Operating Expenses $7.887M $8.488M
YoY Change 86.98% 45.84%
Operating Profit -$7.887M -$8.488M
YoY Change 86.98% 45.84%
Interest Expense $161.0K $172.0K
YoY Change -58.51% -54.74%
% of Operating Profit
Other Income/Expense, Net $161.0K $172.0K
YoY Change -58.51% -54.38%
Pretax Income -$7.726M -$8.316M
YoY Change 101.72% 52.78%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$7.726M -$8.316M
YoY Change 133.91% 63.06%
Net Earnings / Revenue
Basic Earnings Per Share -$6.81 -$0.43
Diluted Earnings Per Share -$6.81 -$0.43
COMMON SHARES
Basic Shares Outstanding 25.13M 17.28M
Diluted Shares Outstanding 1.134M 19.39M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.41M $16.59M
YoY Change -47.34% -51.55%
Cash & Equivalents $16.40M $16.60M
Short-Term Investments
Other Short-Term Assets $1.122M $1.192M
YoY Change -44.78% -65.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables $170.0K $171.0K
Total Short-Term Assets $19.53M $19.72M
YoY Change -43.82% -48.07%
LONG-TERM ASSETS
Property, Plant & Equipment $314.0K $336.0K
YoY Change -19.28% 11.63%
Goodwill $1.465M
YoY Change -73.94%
Intangibles $18.65M $19.18M
YoY Change -1.45% -1.56%
Long-Term Investments
YoY Change
Other Assets $182.0K $176.0K
YoY Change 5.2% 46.67%
Total Long-Term Assets $20.58M $22.68M
YoY Change -23.16% -17.5%
TOTAL ASSETS
Total Short-Term Assets $19.53M $19.72M
Total Long-Term Assets $20.58M $22.68M
Total Assets $40.11M $42.39M
YoY Change -34.83% -35.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $756.0K $935.0K
YoY Change -9.24% 26.18%
Accrued Expenses $3.754M $3.489M
YoY Change -32.84% 91.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $65.00K $62.00K
YoY Change 0.0% -11.43%
Total Short-Term Liabilities $7.323M $6.848M
YoY Change -16.24% -25.03%
LONG-TERM LIABILITIES
Long-Term Debt $98.00K $93.00K
YoY Change -34.67% -38.0%
Other Long-Term Liabilities $8.052M $7.803M
YoY Change -3.63% 4.6%
Total Long-Term Liabilities $8.150M $7.896M
YoY Change -4.17% 3.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.323M $6.848M
Total Long-Term Liabilities $8.150M $7.896M
Total Liabilities $15.47M $14.74M
YoY Change -12.39% -16.68%
SHAREHOLDERS EQUITY
Retained Earnings -$330.5M -$322.8M
YoY Change 8.78% 7.41%
Common Stock $355.3M $349.7M
YoY Change 2.6% 1.01%
Preferred Stock
YoY Change
Treasury Stock (at cost) $288.0K $288.0K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $24.64M $27.65M
YoY Change
Total Liabilities & Shareholders Equity $40.11M $42.39M
YoY Change -34.83% -35.23%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$7.726M -$8.316M
YoY Change 133.91% 63.06%
Depreciation, Depletion And Amortization $33.00K $38.00K
YoY Change -8.33% 26.67%
Cash From Operating Activities -$3.914M -$3.452M
YoY Change 32.45% -11.26%
INVESTING ACTIVITIES
Capital Expenditures $1.000K
YoY Change -90.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.000K
YoY Change -90.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.716M 1.773M
YoY Change 185700.0% -17.15%
NET CHANGE
Cash From Operating Activities -3.914M -3.452M
Cash From Investing Activities -1.000K
Cash From Financing Activities 3.716M 1.773M
Net Change In Cash -198.0K -1.680M
YoY Change -93.57% -4.55%
FREE CASH FLOW
Cash From Operating Activities -$3.914M -$3.452M
Capital Expenditures $1.000K
Free Cash Flow -$3.453M
YoY Change -11.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0000894158
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4068000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4068000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y
tovx Lease Rent Abatement Period1
LeaseRentAbatementPeriod1
P3M
tovx Lessee Operating Lease Short Term Agreement Term
LesseeOperatingLeaseShortTermAgreementTerm
P90D
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12584
dei Entity Registrant Name
EntityRegistrantName
THERIVA BIOLOGICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3808303
dei Entity Address Address Line1
EntityAddressAddressLine1
9605 Medical Center Drive, Suite 270
dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
dei Entity Address Country
EntityAddressCountry
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
dei City Area Code
CityAreaCode
301
dei Local Phone Number
LocalPhoneNumber
417-4364
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TOVX
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25131230
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16593000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23177000
CY2024Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1759000
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1812000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1363000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2414000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
19715000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
27403000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
336000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
422000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
99000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
102000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1519000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1759000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19179000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19755000
CY2024Q2 us-gaap Goodwill
Goodwill
1465000
CY2023Q4 us-gaap Goodwill
Goodwill
5700000
CY2024Q2 tovx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
77000
CY2023Q4 tovx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
78000
CY2024Q2 us-gaap Assets
Assets
42390000
CY2023Q4 us-gaap Assets
Assets
55219000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
935000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
770000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3489000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2995000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
969000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1517000
CY2024Q2 tovx Deferred Research And Development Tax Credit Current
DeferredResearchAndDevelopmentTaxCreditCurrent
880000
CY2023Q4 tovx Deferred Research And Development Tax Credit Current
DeferredResearchAndDevelopmentTaxCreditCurrent
906000
CY2024Q2 us-gaap Loans Payable Current
LoansPayableCurrent
62000
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
63000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
513000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
487000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6848000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6738000
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
6201000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
6274000
CY2024Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
93000
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
162000
CY2024Q2 tovx Deferred Research And Development Tax Credit Noncurrent
DeferredResearchAndDevelopmentTaxCreditNoncurrent
440000
CY2023Q4 tovx Deferred Research And Development Tax Credit Noncurrent
DeferredResearchAndDevelopmentTaxCreditNoncurrent
906000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1162000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1442000
CY2024Q2 us-gaap Liabilities
Liabilities
14744000
CY2023Q4 us-gaap Liabilities
Liabilities
15522000
CY2024Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23113391
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22393158
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17868282
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17148049
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
23000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
18000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
349673000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
346519000
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
720233
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
720233
CY2024Q2 us-gaap Treasury Stock Value
TreasuryStockValue
288000
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
288000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-709000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
32000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-322799000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309318000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
25900000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36963000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
937000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-322800000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16600000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42390000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55219000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1467000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2687000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3401000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4888000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2953000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3133000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6412000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6110000
CY2024Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4068000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4068000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
8488000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
5820000
us-gaap Operating Expenses
OperatingExpenses
13881000
us-gaap Operating Expenses
OperatingExpenses
10998000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8488000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5820000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13881000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10998000
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
173000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
381000
us-gaap Investment Income Interest
InvestmentIncomeInterest
402000
us-gaap Investment Income Interest
InvestmentIncomeInterest
745000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
172000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
377000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
400000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
746000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8316000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5443000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13481000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10252000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-359000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-689000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8316000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5084000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13481000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9563000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19393401
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19393401
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15166209
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15166209
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18270725
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18270725
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15145252
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15145252
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-8316000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-5084000
us-gaap Profit Loss
ProfitLoss
-13481000
us-gaap Profit Loss
ProfitLoss
-9563000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-172000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-51000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-741000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
323000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8488000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5135000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-14222000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-9240000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36963000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
160000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
569000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-5165000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31389000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
172000
CY2024Q2 tovx Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
1839000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
172000
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
988000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-8316000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
25900000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
51830000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
126000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-374000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4478000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
47852000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
146000
CY2023Q2 tovx Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
2156000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
51000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-5084000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
45019000
us-gaap Profit Loss
ProfitLoss
-13481000
us-gaap Profit Loss
ProfitLoss
-9563000
us-gaap Share Based Compensation
ShareBasedCompensation
332000
us-gaap Share Based Compensation
ShareBasedCompensation
272000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-689000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4068000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-73000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
568000
tovx Non Cash Lease Expense
NonCashLeaseExpense
199000
tovx Non Cash Lease Expense
NonCashLeaseExpense
181000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
64000
tovx Increase Decrease In Deferred Research And Development Tax Credit
IncreaseDecreaseInDeferredResearchAndDevelopmentTaxCredit
-444000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1018000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-53000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
179000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-181000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
564000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
335000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-538000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-337000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-234000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-205000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8333000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9502000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
67000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
75000
tovx Proceeds From Issuance Under At Market Offering Net Of Issuance Costs
ProceedsFromIssuanceUnderAtMarketOfferingNetOfIssuanceCosts
1840000
tovx Proceeds From Issuance Under At Market Offering Net Of Issuance Costs
ProceedsFromIssuanceUnderAtMarketOfferingNetOfIssuanceCosts
2156000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1773000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2081000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-26000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-98000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6587000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7536000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23279000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41884000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16692000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34348000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16593000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34248000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
99000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16692000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34348000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
937000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-322800000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16600000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2024Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2024Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q4 us-gaap Goodwill
Goodwill
5700000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4068000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-167000
CY2024Q2 us-gaap Goodwill
Goodwill
1465000
CY2024Q2 us-gaap Goodwill Gross
GoodwillGross
5500000
CY2024Q2 us-gaap Goodwill Fair Value Disclosure
GoodwillFairValueDisclosure
1500000
CY2024Q2 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
6201000
CY2023Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
6274000
CY2024Q2 us-gaap Goodwill Gross
GoodwillGross
5500000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-167000
CY2024Q2 us-gaap Goodwill
Goodwill
1465000
CY2024Q2 us-gaap Goodwill Gross
GoodwillGross
5500000
CY2024Q2 us-gaap Goodwill Fair Value Disclosure
GoodwillFairValueDisclosure
1500000
CY2024Q2 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
6201000
CY2023Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
6274000
CY2024Q2 us-gaap Goodwill Gross
GoodwillGross
5500000
CY2024Q2 tovx Deferred Research And Development Tax Credit Grant Receivable
DeferredResearchAndDevelopmentTaxCreditGrantReceivable
1800000
CY2024Q2 tovx Deferred Research And Development Tax Credit Current
DeferredResearchAndDevelopmentTaxCreditCurrent
880000
CY2024Q2 tovx Deferred Research And Development Tax Credit Noncurrent
DeferredResearchAndDevelopmentTaxCreditNoncurrent
440000
CY2024Q2 tovx Increase Decrease In Deferred Research And Development Tax Credit
IncreaseDecreaseInDeferredResearchAndDevelopmentTaxCredit
-221000
tovx Increase Decrease In Deferred Research And Development Tax Credit
IncreaseDecreaseInDeferredResearchAndDevelopmentTaxCredit
-444000
CY2024Q2 tovx Deferred Research And Development Tax Credit Grant Receivable
DeferredResearchAndDevelopmentTaxCreditGrantReceivable
1800000
CY2024Q2 tovx Deferred Research And Development Tax Credit Current
DeferredResearchAndDevelopmentTaxCreditCurrent
880000
CY2024Q2 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
475000
CY2023Q4 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
491000
CY2024Q2 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
271000
CY2023Q4 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
180000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
233000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
496000
CY2024Q2 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
213000
CY2023Q4 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
1119000
CY2024Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
171000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
128000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1363000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2414000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1220000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1424000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
884000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1002000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
336000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
422000
CY2024Q2 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
475000
CY2023Q4 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
491000
CY2024Q2 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
271000
CY2023Q4 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
180000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
233000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
496000
CY2024Q2 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
213000
CY2023Q4 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
1119000
CY2024Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
171000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
128000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1363000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2414000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1220000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1424000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
884000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1002000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
336000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
422000
CY2024Q2 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
2495000
CY2023Q4 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
1700000
CY2024Q2 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
616000
CY2023Q4 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
843000
CY2024Q2 tovx Accrued Vendor Payments
AccruedVendorPayments
378000
CY2024Q2 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
2495000
CY2023Q4 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
1700000
CY2024Q2 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
616000
CY2023Q4 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
843000
CY2024Q2 tovx Accrued Vendor Payments
AccruedVendorPayments
378000
CY2023Q4 tovx Accrued Vendor Payments
AccruedVendorPayments
452000
CY2024Q2 tovx Accrued Expenses
AccruedExpenses
3489000
CY2023Q4 tovx Accrued Expenses
AccruedExpenses
2995000
CY2024Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
650000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1307000
CY2024Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
190000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
127000
CY2024Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
129000
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
83000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1517000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
934000000000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2023 tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2023Q4 tovx Accrued Vendor Payments
AccruedVendorPayments
452000
CY2024Q2 tovx Accrued Expenses
AccruedExpenses
3489000
CY2023Q4 tovx Accrued Expenses
AccruedExpenses
2995000
CY2024Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
650000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1307000
CY2024Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
190000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
127000
CY2024Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
129000
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
83000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
969000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1517000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2023 tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634426
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.22
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y9M10D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
634426
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.22
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8300000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13500000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5100000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9600000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634426
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.22
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y9M10D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
634426
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.22
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8300000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13500000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5100000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9600000
CY2022Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.00
CY2022Q3 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3000000.0
CY2022Q3 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
1.22
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2459016
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
99000
CY2024Q2 us-gaap Loans Payable Current
LoansPayableCurrent
62000
CY2024Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
93000
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
63000
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
162000
CY2022Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.00
CY2022Q3 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3000000.0
CY2022Q3 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
1.22
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2459016
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
99000
CY2024Q2 us-gaap Loans Payable Current
LoansPayableCurrent
62000
CY2024Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
93000
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
63000
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
162000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
62000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
51000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
32000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
10000
CY2024Q2 tovx Long Term Debt.
LongTermDebt.
155000
CY2024Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P63M
tovx Percentage Of Office Leases Owned By Subsidiary
PercentageOfOfficeLeasesOwnedBySubsidiary
1
tovx Lessee Operating Lease Additional Renewal Term
LesseeOperatingLeaseAdditionalRenewalTerm
P5Y
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
158000
us-gaap Operating Lease Cost
OperatingLeaseCost
315000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
158000
us-gaap Operating Lease Cost
OperatingLeaseCost
303000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
937000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
62000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
51000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
32000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
10000
CY2024Q2 tovx Long Term Debt.
LongTermDebt.
155000
CY2024Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P63M
tovx Percentage Of Office Leases Owned By Subsidiary
PercentageOfOfficeLeasesOwnedBySubsidiary
1
tovx Lessee Operating Lease Additional Renewal Term
LesseeOperatingLeaseAdditionalRenewalTerm
P5Y
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
158000
us-gaap Operating Lease Cost
OperatingLeaseCost
315000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
158000
us-gaap Operating Lease Cost
OperatingLeaseCost
303000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
937000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
331000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
331000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
671000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
671000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
588000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
588000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
368000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
368000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1958000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1958000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
283000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
283000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1675000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1675000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
513000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1162000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
513000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1162000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-001342-index-headers.html Edgar Link pending
0001410578-24-001342-index.html Edgar Link pending
0001410578-24-001342.txt Edgar Link pending
0001410578-24-001342-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20240630.xsd Edgar Link pending
tmb-20240630x10q.htm Edgar Link pending
tmb-20240630x10q001.jpg Edgar Link pending
tmb-20240630xex31d1.htm Edgar Link pending
tmb-20240630xex32d1.htm Edgar Link pending
tmb-20240630_def.xml Edgar Link unprocessable
tmb-20240630_cal.xml Edgar Link unprocessable
tmb-20240630_lab.xml Edgar Link unprocessable
tmb-20240630_pre.xml Edgar Link unprocessable
tmb-20240630x10q_htm.xml Edgar Link completed